Doro AB

  • ISIN: SE0000215493
  • Land: .

Nachricht vom 21.03.2012 | 17:00

Bulletin from Doro AB’s Annual General Meeting 2012


Doro AB 

21.03.2012 17:00
---------------------------------------------------------------------------

Lund, Sweden, 2012-03-21 17:00 CET (GLOBE NEWSWIRE) -- 

At the Annual General Meeting of Doro AB (publ), held on 21 March 2012, it was
resolved, inter alia: 

* to adopt the income statement and balance sheet, and the consolidated income
statement and the consolidated balance sheet; 
* to distribute a dividend of SEK 1 per share for the financial year 2011;
* to discharge from liability the members of the board of directors and the CEO
for the financial year 2011; 
* to re-elect Bo Kastensson, Karin Moberg, Jonas Mårtensson, Jérôme Arnaud and
Charlotta Falvin as members of the board of directors for the period up to and
including the next annual general meeting; 
* to re-elect Bo Kastensson as the chairman of the board of directors;
* remuneration to the board as follows: the chairman receives SEK 350,000 and
other members not employed by the company receive SEK 150,000 each; 
* to adopt principles for the appointment of the nomination committee;
* to authorize the board, for the period until the next annual general meeting,
to resolve, on one or several occasions, to issue not more than 1,930,000
shares without preferential rights for the shareholders. Such new issue
resolution shall include a provision that new shares shall be paid in kind; and 
* to adopt remuneration guidelines with the principal effect that salaries and
other terms of remuneration for the group management shall be on market terms. 



For more information, please contact:
President and CEO Jérôme Arnaud, +46 (0)46 280 50 05,
or Vice President and CFO Annette Borén, +46 (0)706 30 00 09.

This is information that Doro AB (publ) is required to publish in accordance
with the Swedish Securities Markets Act and/or the Swedish Financial Trading
Act. This information was submitted for publication on March 21, 2012 at 5 p.m
CET.
News Source: NASDAQ OMX



21.03.2012 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Doro AB
              
               
              Sweden
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         SE0000215493
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

GBC-Research im Fokus

amp biosimilars AG: Am Anfang einer steilen Wachstumskurve

Mit dem Fokus auf der Entwicklung von Biosimilars adressiert die amp biosimilars AG einen der am stärksten wachsenden Teilbereiche der Pharmabranche. Haupttreiber sind hier die zahlreichen Patentausläufe sowie die hohe Nachfrage nach kostengünstigen Arzneien. Die amp biosimilars AG ist mit ihrem Plattform-Ansatz in der Lage, Biosimilars günstiger, effizienter und schneller zu entwickeln, als es bisher möglich war. Mit der frühzeitigen Auslizenzierung der ersten beiden Projekte wurde bereits der Proof of Concepts erbracht. Wir erwarten den Ausbau der Projektpipeline und haben einen fairen Wert je Aktie von 40,30 € („KAUFEN“) ermittelt.

News im Fokus

Infineon Technologies AG: STARKES WACHSTUM BEI UMSATZ UND ERGEBNIS

30. Juli 2015, 07:30

Aktueller Webcast

Fresenius Medical Care AG & Co. KGaA

Q2 2015 Conference Call

30. Juli 2015

Aktuelle Research-Studie

Nemetschek AG

Original-Research: Nemetschek AG (von Montega AG): Halten

31. Juli 2015